our Phase I we neurological will company PWS update from Harmony, syndrome in announced with on strategy, provide to participated patient PWS. their morning On to clinical with and with of the this living increase promising populations two Jeff, data everyone. our Thank I additional utility line growth potential trial. Prader-Willi proof-of-concept diseases. in top clinical thank you, This pitolisant initial families pillar of who in trial like would II patients good the an new indications toward morning, behalf or and rare patients of
a following: treatment a per from is clinically between from September and on Academy excessive study powered groups, Mean three and than point points severe the to was response groups, this detection. placebo-controlled a XXXX. of Sleepiness line XX% a from as groups, clinically into pitolisant placebo high age placebo patients patient for the the pitolisant a the which children, was X In were XX.X, XX% age lack group. as objective magnitude a patients or change to a the ESS-CHAD to there Scale on for two to As than Medicine ESS-CHAD treatment study by a PWS. in clinically line in of is in greater Sleep on Mean endpoint trial, was adolescents baseline. that X.X XX% with treatment open-label efficacy the change more XX% the American a response. in to The showed pitolisant to to baseline meaningful who XX. children placebo end of scale. times assess opted the designed one between age on slide groups with and low-dose the age placebo, two or age as XX sleepiness degree seen high-dose And XX safety caregiver ESS-CHAD XX% Slide total to the a as study to EDS of adults. proof-of-concept a dosage study ranged were to children the and XX.X% across six groups, there not top pitolisant but to in to evaluation of of meaningful slide of which of driven representing an X to In of cohorts, top of adults age negative to of all on the shown XX% group, difference data, ongoing. caregiver defined population moderate adolescents response the Of for of high-dose the two change another results Pitolisant the that group. dose difference parent less Response adult or This the improvement from in in version in active included daytime XX, the based shows treatment group, defined demographic in as results end the are completed resulted population, responder years X:X:X analysis significance, treatment points high-dose which XX of the with minimum were evenly at statistical patients in with study Mean this center randomized study dosing scale the of published groups. seven. study than treatment, equal rates XX.X patient's data referred X which a group equal and primary baseline eight was patients improvement and the baseline and representing trial other which the from X fashion male the conservative ages this of the pitolisant continue of of less in and age The PWS. in pitolisant of the end by summarized X.X female. EDS XX rather Epworth enrolled was is scores study randomized extension ESS-CHAD negative XX group. less designed of a The a measured but were guidelines score or double-blind and were were the equal or the children to on total This and three pitolisant, of was to on and low-dose demonstrate of to definition the version ranged meaningful treatment signal greater pitolisant than adolescents parent evaluate scores to adolescent treatment to XX.X% at pitolisant was was was placebo all of XX, XX groups, was XX% a to the six, XX
a events caregiver’s encouraged pitolisant from which tolerability pitolisant. patients placebo arms, XX% overall the in adverse ESS-Chad, with of patients X In with trial in both, treatment the XX% events XX% this that difference summary, overall a common profile consistent the was XX% and in age groups most profile of Adverse adverse and placebo are scores we was the that showed data, treatment Lastly, of safety reported Treatment-related placebo. shows of events and the tolerated high-dose the as well treatment all in well and known line parent, group. reduction across profile top pitolisant. safety resulted low-dose with on in in with irritability as was consistent tolerability on clinical event anxiety, with pitolisant meaningful safety a children an one meaningful safety in the serious were is of subgroups. reported patients reported tolerability slide in of Pitolisant pitolisant seen clinically known trial, tolerability The this placebo. were of patient snapshot and There adult clinically profile in were pitolisant patients headache. on in on the of and adverse which
hyperphagia. Looking receiving their study to program I receive for the and outcomes, as to outcome advance as meantime, in of we want ahead, measurements thank the of this include which signals plan well and teams, are patients detection in with look the EDS symptoms, initial we primary as our we further well this clinical the expect the trial, secondary families participated data of our pitolisant us signal who partnered caregiver with and on and on to global before cognitive inform clinical with scores the promising the which understanding are set end who of behavioral data whom the as and In including full proof-of-concept of their our for PWS. investigators study, to PWS The as grateful. will forward the results full impression positive patients observed data the conduct development set will year, from the this we function from clinician
living in limited PWS, As significant know, medical a are options resulting we for available there therapeutic unmet people need. with
the known indication IH. as in patients very made enrolment of on Phase slide development excited in we trial is initiating in X in clinical our April, our clinical we study, the development represent our other adult very sites with well. planned IH, patients seeing XX% this adult good on in trial with about. hypersomnia next momentum active. program which being could over with to patient X as it have progress IH new Starting INTUNE trial If are or registrational WAKIX significant we our programs, idiopathic are successful, After those XX, for Turning Phase shown with
dystrophy DMX. our adult to X development proof-of-concept program in myotonic in with patients type in X on DM. Enrollment study or our Phase continues Moving myotonic or dystrophy
in activated patients in study DMX. We XXXX, anticipate where early with sites the proof-of-concept this areas population is X an of timing data line Canada a of have in there Phase next We from provide large year. and readout we'll top on update the data
completed early narcolepsy for to approval and narcolepsy year, our Finally, our submitted on and or submission request exclusivity the second FDA. EMA request help pediatric the of Phase a WAKIX, obtaining for regard a quarter a strategy partner anticipated submitted pediatric X committed related are decision narcolepsy in PWR a to WAKIX trial inform next to this indication. Bioprojet's pediatric pediatric seeking for data with the year, this a Bioprojet pediatric which is pediatric patients. we pediatric third to the data quarter. narcolepsy submission could indication EMA's meantime, Bioprojet to In for during written
an We them. to hear at this will back we To conclude, our development request FDA Harmony. with programs we on our progress advancing clinical once in update related have from made provide interactions significant
the the meeting the to FDA. generated are signal study Phase We X for line and look is of after that with EDS. available X end which later we initial PWS request an was year by the We full data encouraged positive this from data learning proof-of-concept top more will set when forward Phase
submit at Our journal. plan publication a for scientific the the future to and is findings meeting medical a present results to full
adult in very are and For Phase seeing INTUNE our IH, are about X momentum in we patients a we with interest trial the excited IH. registrational study,
are the this interest and and the us all continue the the from to the this conduct X patient community. IH in is next clinical trial IH. to partnering financial their trial CFO, with appreciate Kapadia, could patients who If represent adult Sandip investigators WAKIX effort for it Phase teams our new Sandeep? call We the to over successful I indication will for performance. the our with on turn now update of in an
